|
Year to Dec 2024
12 months to Dec 31, 2024
|
Year to Dec 2023
12 months to Dec 31, 2023
|
Year to Dec 2022
12 months to Dec 31, 2022
|
Year to Dec 2021
12 months to Dec 31, 2021
|
Year to Dec 2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| Sales of goods | |||||
| Total revenue | |||||
| Cost of goods sold | |||||
| Research and development costs | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Loss on conversion of debt | |||||
| Other income | |||||
| Finance income | |||||
| Finance costs | |||||
| Operating lease interest expense | |||||
| Loss before income taxes | |||||
| Income tax provision (recovery) | |||||
| Net loss | |||||
| Net loss attributable to Nymox shareholders | |||||
| Basic and diluted loss per share | |||||
| Weighted average number of common shares outstanding | |||||
Loading...